摘要：
Heart failure (HF) is a complex syndrome marked by considerable expenditures and elevated mortality and morbidity rates globally. Shenmai injection (SMI), a form of Traditional Chinese Medicine-based therapy, has demonstrated effectiveness in treating HF. Recent research suggests that Traditional Chinese Medicine (TCM) may induce beneficial changes in microbial-host co-metabolism, potentially providing cardiovascular protection. This study used a rat model of hypertensive heart failure (H-HF) to explore the mechanism of SMI. The possible compounds and key targets of SMI against H-HF were investigated using network pharmacology. The pharmacodynamics of SMI were validated using the H-HF animal model, with analysis of fecal gut microbiota integrating metabolomics and 16S rRNA sequencing. Metorigin metabolite traceability analysis and the MetaboAnalyst platform were utilized to explore the action mechanism. To evaluate changes in serum TMAO levels, targeted metabolomics was performed. Finally, the study looked at the intrinsic relationships among modifications in the intestinal flora, metabolite profile changes, and the targets of SMI compounds to clarify how they might be used to treat H-HF. According to metabolomics and 16S rRNA sequencing, by reestablishing homeostasis in the gut microbiota, SMI affects vital metabolic pathways, such as energy metabolism, amino acid metabolism, and bile acid metabolism. Increased serum TMAO levels were identified to be a risk factor for H-HF, and SMI was able to downregulate the levels of TMAO-related metabolites. Network pharmacology analysis identified 13 active components of SMI targeting 46 proteins, resulting in differential expression changes in 8 metabolites and 24 gut microbes. In conclusion, this study highlights the effectiveness of SMI in alleviating H-HF and its potential to modulate microbial-host co-metabolism. Through a comprehensive discussion of the interconnected relationships among the components, targets, metabolites, and gut microbiota, it provided fresh light on the therapeutic mechanism of SMI on H-HF.
摘要：
BACKGROUND: To explore the effects of Buyang Huanwu Decoction (BYHWD) on neurons in the red nucleus of rats with spinal cord injury (SCI) based on autophagy. METHODS: 120 Sprague-Dawley (SD) rats were randomly divided into 6 groups: Control Group, SCI Group, Bafilomycin A1 Group, Rapamycin Group, BYHWD low-dose group (BL Group, 6.25 g/kg), BYHWD high-dose group (BH Group, 25.00 g/kg), with 20 animals in each group. A rat rubrospinal tract (RST) transection model was established and treated for 28 days. The recovery of motor function of rats was observed through inclined plate test and spontaneous upright exploratory behavior test. Nissl's staining was used to observe the cell morphology of injured red nucleus neurons. Reverse Transcription PCR (RT-PCR) and immunofluorescence were used to detect the expression of ATG5 and Beclin1 mRNA. The Western blot method was used to observe the expression levels of Synaptophysin (SYP), Synaptosomal-associated Protein of 25 kDa (SNAP-25), Postsynaptic density protein 95 (PSD-95), ATG5, and Beclin1 proteins in red nucleus tissue. RESULTS: Compared with the SCI group, both BL and BH groups significantly improved the forelimb motor function and improved the status of red nucleus neurons in SCI rats. BYHWD increased SYP, SNAP-25, PSD-95, and decreased the red core Beclin1 and ATG5. CONCLUSIONS: BYHWD enhances synaptic regeneration and limb activity in red nucleus neurons of SCI rats by inhibiting autophagy.
期刊：
International Journal of Biological Macromolecules,2025年304(Pt 1):140763 ISSN：0141-8130
通讯作者：
Shen, L;Chen, W
作者机构：
[Li, Jinxia] Hunan Univ Chinese Med, Changsha 410208, Peoples R China.;[Li, Jinxia] Hunan Univ Chinese Med, Prov Key Lab TCM Diagnost, Changsha 410208, Peoples R China.;[Shen, Li; Ning, Zixin; Yang, Xiaoyu; Gao, Kun] China Acad Chinese Med Sci, Inst Basic Theory TCM, Beijing 100700, Peoples R China.;[Liu, Ying] China Acad Chinese Med Sci, Inst Chinese Mat Med, Beijing 100700, Peoples R China.;[Chen, Wei; Chen, W] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Gen Surg, Hangzhou 310016, Peoples R China.
通讯机构：
[Shen, L ] C;[Chen, W ] Z;China Acad Chinese Med Sci, Inst Basic Theory TCM, Beijing 100700, Peoples R China.;Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Gen Surg, Hangzhou 310016, Peoples R China.
关键词：
Actinidia eriantha polysaccharide;Macrophage;Gastric cancer
摘要：
Actinidia eriantha polysaccharide (AEPS), an active component of the Chinese herbal medicine Radix Actinidia chinensis , has anticancer effects. Here, we investigated the therapeutic potential of AEPS in gastric cancer through in vivo, in vitro, and in silico analyses. In our gastric cancer xenograft mouse model, AEPS effectively reduced tumor volume and weight. In the human gastric adenocarcinoma cell line AGS, AEPS inhibited migration and invasion without affecting proliferation; this result was validated in a fluorescent-labeled lung metastasis mouse model. Mass cytometry revealed that AEPS enhanced macrophage proportions in gastric cancer tissues. Bioinformatics analysis revealed a strong increase in PD-1-regulated M2 macrophage proportions in patients with gastric cancer, shortening their survival time and worsening their prognosis. In the coculture system of interleukin-4-induced human monocytic leukemia cells and AGS cells, AEPS treatment downregulated PD-1/PD-L1 and M2 macrophage–related marker expression but promoted TAM polarization toward the M1 phenotype. These findings facilitated the elucidation of the mechanism underlying the treatment effects of AEPS against gastric cancer. Finally, AEPS–PD-1 antibody combination therapy further enhanced the anticancer effects of AEPS in vivo, suggesting its potential as a basis to develop novel therapeutics for gastric cancer.
Actinidia eriantha polysaccharide (AEPS), an active component of the Chinese herbal medicine Radix Actinidia chinensis , has anticancer effects. Here, we investigated the therapeutic potential of AEPS in gastric cancer through in vivo, in vitro, and in silico analyses. In our gastric cancer xenograft mouse model, AEPS effectively reduced tumor volume and weight. In the human gastric adenocarcinoma cell line AGS, AEPS inhibited migration and invasion without affecting proliferation; this result was validated in a fluorescent-labeled lung metastasis mouse model. Mass cytometry revealed that AEPS enhanced macrophage proportions in gastric cancer tissues. Bioinformatics analysis revealed a strong increase in PD-1-regulated M2 macrophage proportions in patients with gastric cancer, shortening their survival time and worsening their prognosis. In the coculture system of interleukin-4-induced human monocytic leukemia cells and AGS cells, AEPS treatment downregulated PD-1/PD-L1 and M2 macrophage–related marker expression but promoted TAM polarization toward the M1 phenotype. These findings facilitated the elucidation of the mechanism underlying the treatment effects of AEPS against gastric cancer. Finally, AEPS–PD-1 antibody combination therapy further enhanced the anticancer effects of AEPS in vivo, suggesting its potential as a basis to develop novel therapeutics for gastric cancer.
作者机构：
[Li, Liang; Xia, Shuai-shuai; Li, Mei-li; Fan, Ting-ting; Wan, Cai-yun; Li, Si-yuan] Hunan Univ Chinese Med, Prov Key Lab Tradit Chinese Med Diagnost, Changsha 410208, Peoples R China.;[Li, Liang; Xia, Shuai-shuai; Li, Mei-li; Fan, Ting-ting; Wan, Cai-yun; Li, Si-yuan] Hunan Univ Chinese Med, Key Lab TCM Heart & Lung Syndrome Differentiat & M, Changsha 410208, Peoples R China.;[Yin, Jian; Li, Mei-li] Hunan Univ Chinese Med, Dept Anat, Changsha 410208, Peoples R China.;[Li, Qiang] Hunan Brain Hosp, Dept Tradit Chinese Med, Changsha 410007, Peoples R China.
通讯机构：
[Li, L ] H;Hunan Univ Chinese Med, Prov Key Lab Tradit Chinese Med Diagnost, Changsha 410208, Peoples R China.;Hunan Univ Chinese Med, Key Lab TCM Heart & Lung Syndrome Differentiat & M, Changsha 410208, Peoples R China.
摘要：
OBJECTIVE: To investigate whether Buyang Huanwu Decoction (BYHWD) had a good curative effect on the neuroprotection of red nucleus neurons after spinal cord injury (SCI) and the possible molecular mechanism. METHODS: Ninety male Sprague-Dawley rats were divided into 5 groups (n=18 per group) according to a random number table, including the control, model, low- (12.78 g/kg, BL group), medium- (25.65 g/kg, BM group), and high-dose BYHWD groups (51.30 g/kg, BH group). A rubrospinal tract transection model in rats was established, and different doses of BYHWD were intragastrically administrated for 4 weeks. The forelimb locomotor function was recorded using the spontaneous vertical exploration test. Cyclic adenosine monophosphate (cAMP) level in red nucleus was detected through an enzyme-linked immunosorbent assay. The morphology and number of red nucleus neurons were observed using Nissl's staining and axonal retrograde tracing by Fluoro-Gold (FG). The expression of cAMP-dependent protein kinase A (PKA), nuclear factor kappa-B (NF-κB) p65, and brain-derived neurotrophic factor (BDNF) in red nucleus were detected using immunohistochemistry and quantitative real-time polymerase chain reaction. RESULTS: Compared with the control group, the utilization rate of bilateral forelimbs, unilateral right forelimbs, proportion of FG-labeled positive neurons, cAMP level, protein expressions of PKA and BDNF, and BDNF mRNA expression were significantly decreased in the model group (P<0.01), while NF-κB p65 was increased in the model group (P<0.01). Compared with the model group, the utilization rate of bilateral forelimbs and unilateral right forelimbs were significantly higher in the BL, BM and BH groups (P<0.01), the proportion of FG-labeled positive neurons, cAMP level, protein expressions of PKA and BDNF and BDNF mRNA expression in all BYHWD groups were increased (P<0.05 or P<0.01), while NF-κB p65 were decreased in all BYHWD groups (P<0.05 or P<0.01). CONCLUSIONS: BYHWD possesses a sound neuroprotective effect on red nucleus neurons after SCI, and the efficacy was dose-related. The mechanism may be related to regulating the cAMP/PKA/NF-κ B p65 signaling pathway, finally promoting expression of BDNF.
期刊：
Surfaces and Interfaces,2025年:106642 ISSN：2468-0230
通讯作者：
HaoYu Qu
作者机构：
Engineering Technology Research Center for Medicinal and Functional Food, Hunan University of Chinese Medicine, ChangSha, 410208, China;Key Laboratory of TCM Heart and Lung Syndrome Differentiation & Medicated Diet and Dietotherapy, Hunan University of Chinese Medicine, ChangSha, 410208, China;Provincial Key Laboratory of TCM Diagnostics, Hunan University of Chinese Medicine, ChangSha, 410208, China;School of Informatic, Hunan University of Chinese Medicine;[GuangYu Chen; Qun He; PeiPei Zhang; Liang Li; MengZhou Xie] Engineering Technology Research Center for Medicinal and Functional Food, Hunan University of Chinese Medicine, ChangSha, 410208, China<&wdkj&>Key Laboratory of TCM Heart and Lung Syndrome Differentiation & Medicated Diet and Dietotherapy, Hunan University of Chinese Medicine, ChangSha, 410208, China<&wdkj&>Provincial Key Laboratory of TCM Diagnostics, Hunan University of Chinese Medicine, ChangSha, 410208, China
通讯机构：
[HaoYu Qu] E;Engineering Technology Research Center for Medicinal and Functional Food, Hunan University of Chinese Medicine, ChangSha, 410208, China<&wdkj&>Key Laboratory of TCM Heart and Lung Syndrome Differentiation & Medicated Diet and Dietotherapy, Hunan University of Chinese Medicine, ChangSha, 410208, China<&wdkj&>Provincial Key Laboratory of TCM Diagnostics, Hunan University of Chinese Medicine, ChangSha, 410208, China<&wdkj&>School of Informatic, Hunan University of Chinese Medicine
摘要：
Paclitaxel (PTX) is a lipophilic drug with potent anti-cancer activity. However, the conventional preparation method of paclitaxel nanoparticles (PTXNPS) typically requires the use of toxic organic solvents, which not only raises safety concerns for the formulation but also poses significant challenges to the large-scale commercial production of nano-drug formulations. This study developed a method for preparing PTXNPS using polyethylene glycol-polycaprolactone (PEG-PCL) as the nano-drug delivery excipient via the supercritical CO 2 fluid dynamic solvent method (SCDSM). The relevant process parameters were optimized, and a comparative study was conducted by preparing PTXNPS using the classical dichloromethane solvent evaporation method (SEM). Through Transmission Electron Microscopy analysis, the PEG-PCL-encapsulated PTXNPS exhibited a clear, smooth, and uniformly spherical morphology. Successful encapsulation was verified by FT-IR, TGA, DSC, DTG, and XRD analyses. Compared with the SEM, the PTXNPS prepared using the SCDSM demonstrated a narrower particle size distribution, enhanced stability of the aqueous suspension, an increase in encapsulation efficiency by 21.28%, an improvement in drug loading capacity by 20.88%, and no detectable organic solvent residues. Furthermore, SCDSM-prepared PTXNPS effectively reduced the in vitro drug release rate of PTX, significantly increased the AUC 0-∞ and C max of PTX in rat blood, liver, and spleen, prolonged T max , and thereby improved the hepatic and splenic targeting efficacy as well as the overall bioavailability of PTX. The SCDSM method developed in this study integrates nanoparticle preparation, extraction reaction, separation, and drying into a single process, characterized by simplicity and high efficiency. This method avoids the use of toxic or hazardous reagents, thereby offering significant commercial potential, promising prospects for market promotion and popularization, as well as substantial application value.
Paclitaxel (PTX) is a lipophilic drug with potent anti-cancer activity. However, the conventional preparation method of paclitaxel nanoparticles (PTXNPS) typically requires the use of toxic organic solvents, which not only raises safety concerns for the formulation but also poses significant challenges to the large-scale commercial production of nano-drug formulations.
This study developed a method for preparing PTXNPS using polyethylene glycol-polycaprolactone (PEG-PCL) as the nano-drug delivery excipient via the supercritical CO 2 fluid dynamic solvent method (SCDSM). The relevant process parameters were optimized, and a comparative study was conducted by preparing PTXNPS using the classical dichloromethane solvent evaporation method (SEM).
Through Transmission Electron Microscopy analysis, the PEG-PCL-encapsulated PTXNPS exhibited a clear, smooth, and uniformly spherical morphology. Successful encapsulation was verified by FT-IR, TGA, DSC, DTG, and XRD analyses. Compared with the SEM, the PTXNPS prepared using the SCDSM demonstrated a narrower particle size distribution, enhanced stability of the aqueous suspension, an increase in encapsulation efficiency by 21.28%, an improvement in drug loading capacity by 20.88%, and no detectable organic solvent residues. Furthermore, SCDSM-prepared PTXNPS effectively reduced the in vitro drug release rate of PTX, significantly increased the AUC 0-∞ and C max of PTX in rat blood, liver, and spleen, prolonged T max , and thereby improved the hepatic and splenic targeting efficacy as well as the overall bioavailability of PTX.
The SCDSM method developed in this study integrates nanoparticle preparation, extraction reaction, separation, and drying into a single process, characterized by simplicity and high efficiency. This method avoids the use of toxic or hazardous reagents, thereby offering significant commercial potential, promising prospects for market promotion and popularization, as well as substantial application value.
期刊：
Journal of the Science of Food and Agriculture,2025年105(2):1216-1227 ISSN：0022-5142
通讯作者：
Wang, Wei;Jian, YQ
作者机构：
[Xie, Qingling; Wang, Wei; Liang, Ling; Jian, Yuqing; Huang, Qin; Hu, Qiqi; Guo, Tingsi; Yuan, Hanwen; Yang, Yong] Hunan Univ Chinese Med, Innovat Mat Med Res Inst, Sch Pharm, TCM & Ethnomed Innovat & Dev Int Lab, Changsha 410208, Peoples R China.;[Chen, Guangyu] Hunan Univ Chinese Med, Engn Technol Res Ctr Med & Funct Food, Changsha, Peoples R China.;[Chen, Guangyu] Hunan Univ Chinese Med Changsha, Key Lab TCM Heart & Lung Syndrome Differentiat & M, Changsha, Peoples R China.
通讯机构：
[Wang, W; Jian, YQ ] H;Hunan Univ Chinese Med, Innovat Mat Med Res Inst, Sch Pharm, TCM & Ethnomed Innovat & Dev Int Lab, Changsha 410208, Peoples R China.
摘要：
BACKGROUND: Cyclocarya paliurus, as a new food resource, is utilized extensively in human and animal diets due to its bioactive compounds, health benefits, fi ts, and its highly prized sweet fl avor. This study aimed to investigate the sweet-taste ingredient of C. paliurus leaves. RESULTS: Five new dammarane triterpenoid glycosides were isolated and identified fi ed as qingqianliutianosides A-E - E (1-5) 1 - 5 ) by comprehensive spectroscopic data analysis and a single crystal X-ray diffraction experiment. Qingqianliutianoside A (1) 1 ) and qingqianliutianoside C (3), 3 ), present in relatively high quantities in the plant, were shown to exhibit sweetness by sensory evaluation and electronic tongue analysis. Further monitoring was conducted on the content changes in 3 in leaves at different growth stages, indicating that 3 reached its peak content in April and then showed a decreasing trend. Molecular docking studies revealed that T1R2/T1R3 receptors Ser212, Ser105, Thr239, Asn380, Thr305, and Val381 may play critical roles, demonstrating that hydrogen bonding and hydrophobic interactions were the dominant interaction forces between all of the identified compounds and the active sites in the Venus flytrap module of the T1R2/T1R3 receptors. CONCLUSION: Qingqianliutianosides A-E - E are promising natural source sugar substitutes for use in functional foods and beverages. (c) 2024 Society of Chemical Industry.
摘要：
OBJECTIVE: To investigate the relationship between heart failure (HF) and gut microbiota-mediated energy metabolism, and to explore the role of Shenfu Injection in this process. MATERIALS AND METHODS: In this study, Adriamycin-induced chronic heart failure (CHF) rat model was used and randomly divided into the blank control group (Normal, n = 9), HF control group (Model, n = 12), Shenfu Injection treatment group (SFI, n = 9), and positive drug control group (TMZ, n = 9). The changes in gut microbiota structure were analyzed by 16S rRNA high-throughput sequencing, the content of short-chain fatty acids (SCFAs) was detected by targeted metabolomics technology, and cardiac function and energy metabolism-related indicators were evaluated. RESULTS: Myocardial energy metabolism in HF rats was disordered, characterized by reduced fatty acid oxidation, enhanced anaerobic glycolysis of glucose, mitochondrial damage, and decreased ATP content; The gut microbiota of HF rats was imbalanced, with a reduction in beneficial bacteria, an increase in conditional pathogenic bacteria, and impaired intestinal barrier function; Both Shenfu Injection and trimetazidine improved myocardial energy metabolism and cardiac function, but Shenfu Injection was more significant in regulating gut microbiota and improving intestinal health; The production of SCFAs from the gut microbiota of HF rats increased, which may be closely related to myocardial energy metabolism; SCFAs-producing bacteria Akkermansia and Blautia played a key role in the development of HF, and their abundance was positively correlated with SCFAs content. CONCLUSION: Shenfu Injection in treating HF may improve myocardial energy metabolism and intestinal health by regulating gut microbiota, especially the abundance of SCFAs-producing bacteria Akkermansia and Blautia, thereby exerting therapeutic effects. This provides theoretical support for treatment strategies based on gut microbiota.
摘要：
Objective Patients with chronic kidney disease (CKD) exhibit a disproportionately elevated risk of stroke, frequently compounded by renal impairment. Therapeutic strategies for stroke based on Traditional Chinese Medicine's 'kidney–brain axis' theory demonstrate clinical efficacy, indicating that there may be a potential association between chronic kidney disease and stroke, which needs further exploration and verification.
Patients with chronic kidney disease (CKD) exhibit a disproportionately elevated risk of stroke, frequently compounded by renal impairment. Therapeutic strategies for stroke based on Traditional Chinese Medicine's 'kidney–brain axis' theory demonstrate clinical efficacy, indicating that there may be a potential association between chronic kidney disease and stroke, which needs further exploration and verification.
Methods In this study, databases such as GEO, NHANES, and GWAS were used to collect data related to CKD and stroke. GEO gene data enrichment analysis was used to explore possible mediating factors between CKD and stroke. NHANES clinical data were used to verify the GEO data analysis results. Mendelian randomization was used to confirm the causal relationship between CKD and stroke and verify the association effect of mediating factors in these two diseases.
In this study, databases such as GEO, NHANES, and GWAS were used to collect data related to CKD and stroke. GEO gene data enrichment analysis was used to explore possible mediating factors between CKD and stroke. NHANES clinical data were used to verify the GEO data analysis results. Mendelian randomization was used to confirm the causal relationship between CKD and stroke and verify the association effect of mediating factors in these two diseases.
Results Cross-gene analysis and transcription factor analysis of GEO data revealed that lipid-related pathways may have a mediating effect on the relationship between CKD and stroke. Logistic regression analysis based on NHANES data revealed that changes in LDL-C, HDL-C, TC, and TG can affect the occurrence of stroke. Mendelian randomization analysis was used to determine the causal relationship between CKD and stroke and verified the mediating effects of lipid factors, such as LDL-C, HDL-C, TC, and TG, indicating that LDL-C, HDL-C, TC, and TG may be potential mediating factors for these two diseases. Our findings highlight the clinical relevance of lipid pathways in bridging CKD and stroke. By integrating predictive biomarkers and multi-level diagnostics, this study paves the way for AI-driven precision medicine in stroke prevention. Specifically, machine learning approaches could enhance risk stratification of high-risk CKD cohorts, enabling tailored interventions such as lipid-lowering therapies and personalized monitoring protocols. These strategies align with emerging paradigms in healthcare benefits and population-specific management.
Cross-gene analysis and transcription factor analysis of GEO data revealed that lipid-related pathways may have a mediating effect on the relationship between CKD and stroke. Logistic regression analysis based on NHANES data revealed that changes in LDL-C, HDL-C, TC, and TG can affect the occurrence of stroke. Mendelian randomization analysis was used to determine the causal relationship between CKD and stroke and verified the mediating effects of lipid factors, such as LDL-C, HDL-C, TC, and TG, indicating that LDL-C, HDL-C, TC, and TG may be potential mediating factors for these two diseases. Our findings highlight the clinical relevance of lipid pathways in bridging CKD and stroke. By integrating predictive biomarkers and multi-level diagnostics, this study paves the way for AI-driven precision medicine in stroke prevention. Specifically, machine learning approaches could enhance risk stratification of high-risk CKD cohorts, enabling tailored interventions such as lipid-lowering therapies and personalized monitoring protocols. These strategies align with emerging paradigms in healthcare benefits and population-specific management.
Conclusion This study provides new insights into the interactive relationship between CKD and stroke and provides a scientific basis for the process of syndrome differentiation and the treatment of stroke under the guidance of the "kidney–brain correlation". Moreover, the influence of mediating factors related to lipid metabolism on the occurrence of these two diseases was investigated, which deepened researchers' understanding of the potential association mechanism between the two diseases.
This study provides new insights into the interactive relationship between CKD and stroke and provides a scientific basis for the process of syndrome differentiation and the treatment of stroke under the guidance of the "kidney–brain correlation". Moreover, the influence of mediating factors related to lipid metabolism on the occurrence of these two diseases was investigated, which deepened researchers' understanding of the potential association mechanism between the two diseases.
摘要：
Objective Based on metabolomics,it explored the differential metabolites screened by Chinese herbal medicines(compound/single decoction pieces)for the treatment of coronary heart disease with blood stasis syndrome in different species and summarized the biomarkers and related metabolic pathways after the intervention of Chinese herbal medicines.Methods The metabonomics study of traditional Chinese medicine(compound/single decoction pieces)in the treatment of coronary heart dis-ease with blood stasis syndrome was retrieved from CNKI,Wanfang database,VIP database,EMBASE,PubMed,the Cochrane Li-brary and web of science database.The differential metabolites included in the study were summarized.The metabolites were anno-tated by HMDB,PubChem subs and KEGG,and the metabolite path visualization was analyzed by metPA network software.Re-sults A total of eight publications were included in this study,and a total of 89 differential metabolites were counted after counting the recurring metabolites in both species that were mainly involved in 132 metabolic pathways.Through the analysis of pathway to-pology and the statistics of repeated metabolic pathways,16 metabolic pathways with P values less than 0.05 were selected as the metabolic pathways of traditional Chinese medicine(compound/single decoction pieces)in the treatment of coronary heart disease with blood stasis syndrome in different species.For the metabolites enriched in various differential metabolic pathways,the metab-olites repeatedly screened in different studies included phenylalanine,glutamine,glycine,citric acid,choline,creatine,lactic acid,β-glucose,α-glucose and arachidonic acid.Conclusion The herbs(compound/single decoction pieces)used for the treatment of coronary heart disease with blood stasis syndrome in various studies were represented by Xuefu Zhuyu Decoction(血府逐瘀汤),Taohong Siwu Decoction(桃红四物汤),Yangxin Tongmai Formula(养心通脉方)and Suhexiang(Styrax).Bioinformatics analysis based on metabolomics of Chinese herbal medicines(compound/single decoction pieces)for the treatment of coronary heart disease with blood stasis showed that the mechanism of action involves various aspects of glucose metabolism,amino acid metabolism,energy metabolism,choline metabolism and fatty acid metabolism,in which the basic tricarboxylic acid cycle is in-volved.The differential metabolites related to coronary heart disease with blood stasis syndrome,including lactic acid,glucose,cit-ric acid,arachidonic acid,creatine,phenylalanine,choline,glutamine and glycine,were summarized.
作者机构：
[Lei, Huijun; Tang, Li; Li, Liang; Yang, Ping; Fu, Yue; Chen, Cheng] Hunan Univ Chinese Med, Hunan Brain Hosp, Clin Med Sch, Dept Chinese & Western Integrat Med, Changsha 410007, Peoples R China.;[Lei, Huijun; Fu, Yue; Li, Liang; Chen, Guangyu; Xie, Mengzhou; Chen, Cheng; Xia, Shuaishuai] Hunan Univ Chinese Med, Prov Key Lab TCM Diag, Changsha 410208, Hunan, Peoples R China.;[Lei, Huijun; Fu, Yue; Li, Liang; Xie, Mengzhou; Chen, Cheng; Xia, Shuaishuai] Hunan Univ Chinese Med, Key Lab TCM Heart & Lung Syndrome Differentiat & M, Changsha 410208, Hunan, Peoples R China.;[Li, F; Li, Feng] Univ So Calif, Sch Dent, Los Angeles, CA 90089 USA.;[Guo, Yan; Yang, Ping] Xi An Jiao Tong Univ, Biomed Informat & Genom Ctr, Sch Life Sci & Technol, Key Lab Biomed Informat Engn Minist Educ, Xian 710049, Shaanxi, Peoples R China.
通讯机构：
[Li, F ] U;[Li, L ] H;Hunan Univ Chinese Med, Hunan Brain Hosp, Clin Med Sch, Dept Chinese & Western Integrat Med, Changsha 410007, Peoples R China.;Univ So Calif, Sch Dent, Los Angeles, CA 90089 USA.
摘要：
Gastric cancer (GC) is one of the most prominent malignancies that originate in the epithelial cells of the gastric mucosa and is one of the main causes of cancer-related mortality worldwide. New circulating biomarkers of exosomal RNA might have great potential for non-invasive early prognosis of GC. Sijunzi Decoction (SJZD) is a typical representative formula of the method of benefiting Qi and strengthening the spleen in Traditional Chinese Medicine (TCM). However, the effects and mechanism of SJZD in treating GC remain unclear. This study looked for biomarkers of exosomal RNA for early prognosis of GC, and explored the mechanism of SJZD in treating GC. A gastric cancer model with spleen deficiency syndrome was established in nude mice, and the curative effects of SJZD were investigated. Differentially expressed miRNAs in plasma and saliva exosomes were sequenced and analyzed. Potential target genes of these miRNAs were predicted and applied for Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) signaling pathway enrichment annotation. Overlapping miRNAs in saliva and plasma samples were analyzed, and qRT-PCR was performed for verification. miR-151a-3p was selected, and qRT-PCR further determined that miR-151a-3p was downregulated in saliva and plasma exosomes from the SJZD group. The intersected miR-151a-3p target genes were predicted and enriched in the extrinsic apoptotic signaling pathways. SJZD significantly ameliorates gastric cancer with spleen deficiency syndrome in mouse models, and exosomal miRNAs, particularly miR-151-3p, might be modulated by SJZD in plasma and saliva. The exosomal miR-151-3p in saliva may serve as a non-invasive potential marker for gastric cancer diagnosis and prognosis.
Gastric cancer (GC) is one of the most prominent malignancies that originate in the epithelial cells of the gastric mucosa and is one of the main causes of cancer-related mortality worldwide. New circulating biomarkers of exosomal RNA might have great potential for non-invasive early prognosis of GC. Sijunzi Decoction (SJZD) is a typical representative formula of the method of benefiting Qi and strengthening the spleen in Traditional Chinese Medicine (TCM). However, the effects and mechanism of SJZD in treating GC remain unclear. This study looked for biomarkers of exosomal RNA for early prognosis of GC, and explored the mechanism of SJZD in treating GC. A gastric cancer model with spleen deficiency syndrome was established in nude mice, and the curative effects of SJZD were investigated. Differentially expressed miRNAs in plasma and saliva exosomes were sequenced and analyzed. Potential target genes of these miRNAs were predicted and applied for Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) signaling pathway enrichment annotation. Overlapping miRNAs in saliva and plasma samples were analyzed, and qRT-PCR was performed for verification. miR-151a-3p was selected, and qRT-PCR further determined that miR-151a-3p was downregulated in saliva and plasma exosomes from the SJZD group. The intersected miR-151a-3p target genes were predicted and enriched in the extrinsic apoptotic signaling pathways. SJZD significantly ameliorates gastric cancer with spleen deficiency syndrome in mouse models, and exosomal miRNAs, particularly miR-151-3p, might be modulated by SJZD in plasma and saliva. The exosomal miR-151-3p in saliva may serve as a non-invasive potential marker for gastric cancer diagnosis and prognosis.
